Squamous Head and Neck Cancer
Showing 1 - 25 of >10,000
Needs and Preferences of Patients With Head-neck Cutaneous SCC
Active, not recruiting
- Cutaneous Squamous Cell Carcinoma
- +10 more
- Regular care with additional administration of a semi-structured interview
-
Maastricht, NetherlandsMaastricht University Medical Center+
Sep 13, 2023
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Nashville (biological, other,
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Panitumumab
- +9 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Jun 4, 2023
Head Neck Cancer, Head and Neck Squamous Cell Carcinoma Trial (ALE.C04, Pembrolizumab)
Not yet recruiting
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- (no location specified)
Sep 19, 2023
Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable Trial in Guangzhou (Cadonilimab, Docetaxel, Cisplatin)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Locally Advanced Operable
- Cadonilimab
- +2 more
-
Guangzhou, Guangdong, China
- +1 more
Sep 4, 2023
Head Neck Cancer, Head and Neck Tumors, Squamous Cell Carcinoma of Head and Neck Trial in Chicago (Xevinapant, Carboplatin,
Not yet recruiting
- Head and Neck Cancer
- +2 more
- Xevinapant
- +3 more
-
Chicago, IllinoisUniversity of Chicago Medicine Comprehensive Cancer Center
Oct 25, 2023
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer
- Tislelizumab
- +2 more
- (no location specified)
Jun 9, 2023
Following Salvage Surgery for RESidual or reCurrent sqUamous
Not yet recruiting
- Head and Neck Cancer
- Molecular Analyses
- (no location specified)
Mar 28, 2023
Squamous Cell Carcinoma of Head and Neck Trial in Toronto (fMRI, Oral Pimonidazole)
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- fMRI
- Oral Pimonidazole
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Center
Oct 9, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)
Not yet recruiting
- Sinonasal Cancer
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jun 5, 2023
Prognostic Immune Biomarkers in HNSCC
Completed
- Head and Neck Cancer
- Squamous Cell Carcinoma
- Tumour immunoprofile evaluation
-
Ostrava, Moravian-Silesian Region, CzechiaUniversity Hospital Ostrava
Jul 3, 2023
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Nashville (drug, other,
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Panitumumab-IRDye800
- +5 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Jul 13, 2023
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and
Recruiting
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck
- +4 more
- Cemiplimab
-
Houston, TexasM D Anderson Cancer Center
Jan 17, 2023
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)
Not yet recruiting
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GB1211
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 19, 2023
Oligometastatic Squamous Cell Carcinoma of the Head and Neck Trial (Pembrolizumab, stereotattic ablation radiotherapy (SABR))
Not yet recruiting
- Oligometastatic Squamous Cell Carcinoma of the Head and Neck
- Pembrolizumab
- stereotattic ablation radiotherapy (SABR)
- (no location specified)
Apr 14, 2023
Locally Advanced Head and Neck Squamous Cell Carcinoma Trial in Tianjin (Toripalimab, Stereotactic Body Radiation Therapy
Not yet recruiting
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Toripalimab
- Stereotactic Body Radiation Therapy (SBRT)
-
Tianjin, China
- +1 more
May 16, 2023
Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)
Not yet recruiting
- Head Neck
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Sep 14, 2023
Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Chengdu (Netopitam Palonosetron capsules and dexamethasone)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Netopitam Palonosetron capsules and dexamethasone
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital and Research Institute
Oct 22, 2023
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Panitumumab
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 16, 2023
HLA-DR in Cell Cultures Isolated From Primary Squamous Cell
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Cancer
- cell culture
-
Roma, Lazio, ItalyFondazione Policlinico Universitario Gemelli, Irccs
Sep 11, 2023
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Cancer of Head and Neck, Head Neck Cancer, Tumors, Head and Neck Trial in Boston, Saint Louis, New York (biological, procedure,
Active, not recruiting
- Cancer of Head and Neck
- +5 more
- MK-3475 (neoadjuvant)
- +6 more
-
Boston, Massachusetts
- +2 more
Dec 9, 2022
Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- +3 more
- Pembrolizumab
- +3 more
-
Boston, Massachusetts
- +1 more
Feb 11, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in Portland (Intratumoral Ipilimumab)
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Intratumoral Ipilimumab
-
Portland, OregonPortland Providence Medical Center
Jan 8, 2023